Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.
The transaction is expected to close on Dec 31, 2025.
Shareholders will retain 10% of the shareholding in Earth Vision Bio post-acquisition.
Sale Agreement
Nutriband Inc. to sell majority stake in subsidiary for $5M USD.
Retained Shareholding
Shareholders to retain 10% in Earth Vision Bio post-acquisition.
Proceeds Usage
Proceeds to fund further development of AVERSA Fentanyl.
Product Potential
AVERSA Fentanyl expected annual sales of $80M-$200M in the US.
- The sale will provide funding for the development of AVERSA Fentanyl, aiming to be the first abuse-deterrent opioid patch.
- Nutriband Inc. is focusing on sustainability and innovation in product development.
This strategic agreement marks Nutriband's commitment to innovative pharmaceutical solutions and sustainable business practices.